Health ❯Healthcare ❯Pharmaceuticals

Obesity Treatment

Wegovy GLP-1 Drugs Weight Loss Drugs GLP-1 Medications Clinical Trials Weight Loss Medications CagriSema GLP-1 Therapy Wegovy's Heart Benefits Ozempic Tirzepatide MariTide Mounjaro Drug Pricing Semaglutide Drugs Prescription Medications Semaglutide Novo Nordisk Monlunabant Drug Recommendations Clinical Research Drug Efficacy

UK Mounjaro Orders Frozen Ahead of Price Hike as Korea Confronts Soaring Wegovy Use

Health bodies urge patients to seek supervised prescribing rather than bulk buying or turning to unlicensed sources.

Eli Lilly’s Oral Obesity Pill Triggers Stock Slide After Modest Weight-Loss Results

Novo Nordisk Cuts 2025 Outlook and Names New CEO as Shares Plunge

Meta-Analysis Finds Predictable Weight Rebound After Stopping Anti-Obesity Drugs

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

France to Let All Doctors Prescribe Wegovy and Mounjaro Starting June 23

UK to Trial Pharmacy-Based NHS Weight-Loss Jab Prescriptions

GLP-1 Drugs Like Ozempic Show Promise in Reducing Cravings for Alcohol and Cocaine

Weight Loss Industry Transformed by New Drugs and Emerging Alternatives

Novo Nordisk Shares Plunge After Weight-Loss Drug Trial Falls Short

FDA Ends Shortage of Eli Lilly’s Weight-Loss Drug, Restricts Copycat Versions

Novo Nordisk Urges FDA to Ban Compounded Versions of Ozempic and Wegovy

Novo Nordisk Launches Wegovy in France Without Reimbursement

Novo Nordisk's Obesity Pill Shows Modest Results, Stocks Drop

Study Identifies Key Factors Influencing Weight Loss on GLP-1 RA Medications

Novo Nordisk's Amycretin Pill Shows Promising Weight Loss Results in Early Trial

New Studies Confirm Safety of Semaglutide for Mental Health

Surge in GLP-1 Drugs for Weight Loss Sparks Concerns Over Diabetes Treatment

Wegovy Approved for Heart Disease Treatment in Major FDA Decision